Agostino Fracasso

Title: Agostino Fracasso: Innovator in Peritoneal Dialysis

Introduction

Agostino Fracasso is a notable inventor based in Mogliano V., Italy. He has made significant contributions to the field of medicine, particularly in the area of peritoneal dialysis. His innovative approach has led to advancements in the treatment of patients suffering from chronic renal insufficiency.

Latest Patents

Agostino Fracasso holds a patent for the "Use of some glycosaminoglycans in the peritoneal dialysis." This patent describes the application of glycosaminoglycans such as sulodexide, low molecular weight heparin, and low molecular weight dermatan sulfate in treating patients undergoing peritoneal dialysis. The effectiveness of these substances has been demonstrated through pharmacological studies on nephrectomized rats and clinical studies involving patients subjected to Continuous Ambulatory Peritoneal Dialysis (CAPD). The studies revealed a significant increase in the peritoneal transport of urea and creatinine, along with a notable decrease in protein loss in the peritoneal effluent. Importantly, no significant changes in ultrafiltration capacity or hemorrhagic-coagulative complications were observed during the research.

Career Highlights

Agostino Fracasso is associated with Alfa Wassermann S.p.a., a company known for its commitment to healthcare innovation. His work has been instrumental in enhancing treatment options for patients with chronic renal conditions.

Collaborations

Throughout his career, Fracasso has collaborated with esteemed colleagues such as Bruno Baggio and Giorgio Bazzato. These partnerships have contributed to the advancement of research and development in the medical field.

Conclusion

Agostino Fracasso's contributions to peritoneal dialysis exemplify the impact of innovative thinking in medicine. His patent and collaborative efforts continue to influence the treatment of chronic renal insufficiency, showcasing the importance of research and development in healthcare.